Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024. In the quarter to June 2026, revenue grew 69.8%, EPS fell 30.0% and free cash flow fell 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

16.47 0.93 −5.34%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(93.04%) (52.09%) (50.14%) (64.03%)
ROA
(80.08%) (46.00%) (46.67%) (59.03%)
ROIC
0.00% 0.00% (2,490.49%) (3,322.99%)
Return on Tangible Assets
(85.66%) (33.69%) (38.46%) (48.90%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(2.18) (2.30) (1.82) (1.93)
Free Cash Flow
(191.84) (200.60) (205.52) (219.09)
Capital Expenditures
(6.81) (9.68) (9.02) (10.29)
Other line items
Cash ROIC
(35.75%) (15.58%) (17.55%) (20.96%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Operating CF/Net income
0.83 0.90 0.87 0.82
Depreciation/Fixed assets
(0.05) 0.01 0.06 0.12
Capex/Depreciation
11.33 (83.49) (9.39) (4.76)
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(2.10) (2.19) (1.74) (1.84)
Capex per Share
(0.08) (0.11) (0.08) (0.09)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates